BioMarin Pharmaceutical Inc. (BMRN) Announces Selection Of Factor VIII Gene Therapy Drug Development Candidate BMN 270 For The Treatment Of Hemophilia A
1/13/2014 9:31:47 AM
SAN RAFAEL, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has selected an AAV-factor VIII vector, BMN 270, to develop for the treatment of hemophilia A and has initiated IND-enabling studies. BioMarin expects to initiate clinical studies with BMN 270 in early 2015. The Company's gene therapy program for hemophilia A was originally licensed from University College London (UCL) and St. Jude Children's research Hospital in February 2013 and has since been developed at BioMarin's facilities.
Help employers find you! Check out all the jobs and post your resume.
comments powered by